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Abstract
SHROB rats have been suggested as a model for metabolic syndrome (MetS) as a situation prior to the onset of CVD or type-
2 diabetes, but information on descriptive biochemical parameters for this model is limited. Here, we extensively evaluate
parameters related to CVD and oxidative stress (OS) in SHROB rats. SHROB rats were monitored for 15 weeks and compared
to a control group of Wistar rats. Body weight was recorded weekly. At the end of the study, parameters related to CVD and
OS were evaluated in plasma, urine and different organs. SHROB rats presented statistically significant differences from
Wistar rats in CVD risk factors: total cholesterol, LDL-cholesterol, triglycerides, apoA1, apoB100, abdominal fat, insulin, blood
pressure, C-reactive protein, ICAM-1 and PAI-1. In adipose tissue, liver and brain, the endogenous antioxidant systems were
activated, yet there was no significant oxidative damage to lipids (MDA) or proteins (carbonylation). We conclude that
SHROB rats present significant alterations in parameters related to inflammation, endothelial dysfunction, thrombotic
activity, insulin resistance and OS measured in plasma as well as enhanced redox defence systems in vital organs that will be
useful as markers of MetS and CVD for nutrition interventions.
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Introduction
The combination of CVD risk factors known as metabolic
syndrome (MetS) is becoming a major public health problem
which now affects 20%–30% of the adult population in developed
countries [1]. The risk factors include abdominal obesity,
hyperglycaemia, hypertension and/or hypertriglicerydaemia asso-
ciated with a sedentary lifestyle [2]. The main underlying disorder
in MetS appears to be insulin resistance, i.e., an impairment of
insulin action within tissues (mainly muscle, liver and adipose
tissues) that has been related to chronic low-level inflammation as
well as oxidative stress (OS), as second-order underlying mecha-
nisms for this pathological condition [3,4]. The factors defining
MetS may lead to the onset of type-2 diabetes and CVD. This is
the main reason why the study of the factors underlying MetS can
be clinically useful.
There is wide interest in the development of strategies for the
prevention of MetS, mainly via two different approaches: a)
pharmacology – based on the use of drugs such as certain statins or
AMPK (59 adenosine monophosphate-activated protein kinase)
activating agents [5,6]; and b) nutrition–based on diet supple-
mentation with functional compounds, e.g., proanthocyanidins [7]
or iminosugars [8].
To test the efficacy of the different approaches, several animal
models of MetS have been suggested, in which MetS is either
induced by the diet [9,10] or results from some genetic alteration.
Most of the genetically modified animals present mutations in the
gene that codes for the leptin receptor [11], which impairs the
capacity of leptin to regulate food intake and eventually leads to
the development of insulin resistance. One such model is SHROB
(spontaneously hypertensive obese) rats, also called Koletsky rats
[12,13]. SHROB rats were generated by crossing a female
spontaneously hypertensive rat (SHR), obtained by breeding high-
blood-pressure Wistar-Kyoto rats, with a normotensive Sprague
Dawley male, from which a single homozygous recessive trait
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appeared. That trait is a nonsense mutation in the leptin receptor,
designated fak, which results in a premature stop codon in the
extracellular domain of the leptin receptor that circumvents the
process of transduction and thereby truncates all the leptin
receptors [14,15]. SHROB rats, homozygous for this mutation,
are therefore characterized by monogenetic obesity combined with
a hypertensive background for which several phenotype aspects
have been described, including hyperinsulinaemia, hyperlipidae-
mia and nephropathy [15]. SHROB rats are thus a model for
MetS, in accordance with some of its currently accepted defining
factors, i.e., insulin resistance, hypertension, increased plasma
triglyceride levels and obesity [16]. It has also been suggested that
in SHROB rats hyperinsulinaemia is not accompanied by
hyperglycaemia, this model would be especially useful for the
study of the prediabetic state [17], in contrast to other animal
models (e.g. Zucker rats) which develop type-2 diabetes.
Despite its use as a model of MetS, a complete description of the
SHROB rat phenotype, in relation to markers related to CVD and
particularly OS, is lacking. Moreover, studies with SHROB rats
have compared them with SHR, spontaneously hypertensive rats
[15,18], a rat that is already mutated and in which several
parameters are altered, and not with either of the original rat
strains from which these rats were derived, i.e., Sprague-Dawley or
Wistar Kyoto (WKY) rats.
The aim of this work is to complete a phenotypic description of
SHROB rats using previously unexplored parameters related to
CVD, and compare it with that of non-mutated WKY rats. We
obtained new data of relevance for the use of SHROB rats in
nutrition studies.
Materials and Methods
Materials and reagents
The A04 diet was from Harlan Iberica (Panlab S.L., Barcelona,
Spain). Soybean oil, obtained from unrefined organic soy oil (first
cold pressing), was from Clearspring Ltd. (London, UK).
Ketamine chlorhydrate was from Merial Laboratorios (Barce-
lona, Spain). Xylacine was from Quimica Farmaceutica (Barce-
lona, Spain). [2H4]-15-F2t-IsoP, 15-F2t-IsoP and 15-F2t-IsoP
methyl ester were obtained from Cayman Chemical (Ann Arbor,
MI, USA). 2,3,4,5,6-Pentafluorobenzyl (PFB) bromide, N,N-
diisopropylethylamine (DIPE), acetonitrile, anhydrous sodium
sulphate, heptane, phenylmethylsulphonyl fluoride (PMSF), di-
thiothreitol (DTT), iodoacetamide, ethylenediaminetetraacetic
acid (EDTA), Tris-HCl, 3,3-cholaminopropyl-dimethylammonio-
1-propanesulphonate (CHAPS), anhydrous magnesium chloride,
bicinchoninic acid (BCA), 2,29-Azobis(2-amidinopropane) dihy-
drochloride (AAPH), 6-hydroxy-2,5,7,8-tetramethylchroman-2-
carboxylic acid (Trolox), fluorescein (sodium salt), acetone,
phosphomolybdic acid, Bradford reagent, NADPH (b- Nicotin-
amide adenine dinucleotide 29-phosphate reduced tetrasodium salt
hydrate), glutathione reductase (GR from baker’s yeast), L-
glutathione reduced (GSH minimum 99%), t- tert-butyl hydro-
peroxide (t-BuOOH)) and L-glutathione oxidized (GSSG) were all
obtained from Sigma-Aldrich (St. Louis, MO, USA). N,O-
bis(trimethylsilyl)trifluoro-acetamide (BSTFA) was from Supelco
(Bellefonte, PA, USA). Hydrochloric acid fuming 37%, ethanol
absolute, ethyl acetate, methanol, chloroform, Na2CO3,
NaHCO3, EDTA Na
2+, o-phthalaldehyde (OPT), N-ethylmalei-
mide (NEM) and thiobarbituric acid were purchased from Merck
KGaA (Darmstadt, Germany). Fluorescein-5-thiosemicarbazide
(FTSC) was purchased from Invitrogen (Carlsbad, CA, USA).
ProteoBlock protease inhibitor cocktail was purchased from
Thermo Fisher Scientific Inc. (Rockford, IL, USA). Urea,
thiourea, SDS, glycine and glycerol were obtained from USB
(Cleveland, OH, USA). Ammonium persulphate (APS), IPG
buffer, pharmalyte 3-10; bromophenol blue and 1,2-bis(dimethy-
lamino)-ethane (TEMED) were purchased from GE Healthcare
Bio-Sciences AB (Uppsala, Sweden). Acrylamide, bis (N,N9-
methylene-bis-acrylamide) and the Bio-Rad protein assay were
obtained from Bio-rad (Hercules, CA, USA). Drabkin Reagent
and albumin were purchased from Quı´mica Clinica Aplicada
(Tarragona, Spain). Na2HPO4, NaH2PO4, NaCl, epinefrine,
KH2PO4, K2HPO4, trichloroacetic acid (TCA) and NaOH were
purchased from Panreac Quı´mica (Barcelona, Spain). Water for
the assay solutions was obtained using a Milli-Q water purification
system from Millipore Corporation (Billerica, MA, USA).
Animals
Seven female, 11- to 14-week-old, spontaneously hypertensive
obese rats (SHROB) (Charles River Laboratories, Wilmington,
MA, USA) and seven female, 11-week-old WKY rats (control
group) (Janvier, Le Genest-St-Isle, France) were used. They were
kept away from male rats to minimize hormonal alterations.
Experimental design
The rats were kept in Macrolon cages (n= 2–3/cage,
42562656180 mm) under controlled conditions of stable humid-
ity (50610%), and temperature (2262uC) with a 12:12-h light/
dark cycle. All the groups were fed a standard pelleted A04 diet,
given water (Ribes, Barcelona, Spain) ad libitum and administered
a weekly oral dose of 0.8 mL/kg of soybean oil for 13-weeks-fatty
acid composition provided as Table S1. The additional dose of fat
(weekly excess of 5–10% of fat intake) was intended to accelerate
the appearance of alterations in CV risk factors and OS related
parameters. At week 15, one week after the last intragastric dose of
soybean oil and oral glucose tolerance test (OGTT)—see below—
the rats were fasted overnight, anesthetized intraperitoneally with
ketamine and xylacine (80 mg/kg and 10 mg/kg body weight
respectively), and then killed by exsanguination. All the procedures
follow the European Union guidelines for the care and manage-
ment of laboratory animals and all efforts were made to minimize
suffering. The pertinent permission for this specific study was
obtained from the CSIC (Spanish Research Council) Subcommit-
tee of Bioethical Issues (ref. AGL2009-12 374-C03-03).
Sample collection
For urine collection, at week 12 of the experiment, the rats were
placed in metabolic cages and deprived of food for 18 h; the
animals had previously been acclimated to the metabolic cages. At
the end of the experimental period, after one week of recuperation
since the final intragastric dose of soybean oil, blood was collected
by cardiac puncture under anaesthesia. Plasma, serum and
erythrocytes were collected. Tissue samples collected from heart,
brain, liver, and kidney were washed with 0.9% NaCl solution and
immediately frozen in liquid nitrogen. Abdominal fat was weighed
and immediately frozen. All the samples were stored at 280uC
pending analysis. Before analysis, tissue samples were homoge-
nized with sodium phosphate buffer and ultra-centrifuged.
Cardiovascular disease risk factors
Body weight was monitored weekly throughout the experiment.
Determination of plasma lipid profile. Total plasma
cholesterol (CHOL), LDL-cholesterol (LDLc), HDL-cholesterol
(HDLc) and triglycerides (TG) were measured by spectrophoto-
metric methods using the corresponding kits from Spinreact
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(Girona, Spain). ApoA1 and ApoB100 were measured using
ELISA kits purchased from Cusabio Biotech (Hubei, China)
Determination of glycaemia. Blood glucose levels were
measured by the enzyme electrode method using an Ascensia
ELITE XL blood glucose meter from (Bayer Consumer Care
(Basel, Switzerland). Plasma insulin was measured using ELISA
kits from Millipore (Billerica, MA, USA). Homeostasis model
assessments (HOMA) were calculated by applying the formula:
fasting plasma glucose (mg/dL) times fasting insulin (mU/L)
divided by 405 [19]. Glycated Hb was measured using a
spectrophotometric kit from Spinreact. All these measurements
were carried out at the end of the study.
An OGTT was conducted at week 14 of the experiment after
18 h of food deprivation. Rats were administered a glucose dose of
2 g/kg body weight by gastric probe using a 29% glucose solution.
The glucose concentration was measured by the enzyme electrode
method, using single drops of blood taken from the saphenous vein
at 0, 15, 30, 45, 60, 90 and 120 min after glucose administration.
The AUC for serum glucose was calculated over the 2 h period.
This test was carried out 1 week after the last intragastric dose of
soybean oil.
Blood pressure. Systolic and diastolic blood pressure were
measured at week 13 of the experiment. In a quiet place, at an
established time to reduce circadian rhythm interference, the rats
were restrained in a rat pocket and maintained at 32uC. Systolic
and diastolic blood pressure were measured three times by the tail-
cuff method, using a non-invasive automatic blood pressure
analyser (Panlab, Barcelona, Spain) as previously described [20].
Data are presented as the mean of three measurements.
Markers of endothelial function, inflammation and
thrombotic activity. The corresponding ELISA kits from
Cusabio Biotech (Hubei, China) were used to measure the
following parameters in plasma: vascular cell adhesion molecule-
1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) as
markers of endothelial function; C-reactive protein (CRP) as an
inflammation marker.; plasminogen activator inhibitor-1 (PAI-1)
as a marker of thrombotic activity.
Endogenous antioxidant systems
Activity of superoxide dismutase (SOD) and catalase
(CAT). SOD and CAT activities were measured using standard
spectrophotometric methods [21,22] in the following samples:
erithrocytes (0.23–1.84 mL and 0.5 mL, respectively), liver (167–
417 mg and 1.25 mg, respectively), abdominal fat (1.6–4 mg and
12 mg, respectively), kidney (667–1667 mg and 10 mg, respective-
ly), heart (333–833 mg and 5 mg, respectively) and brain (833–
417 mg and 5 mg, respectively).
Glutathione system. Glutathione peroxidase (GPx) and
glutathione reductase (GR) activities were measured by spectro-
photometric methods [23,24]. Glutathione (GSH) and glutathione
disulphide (GSSG) were determined using fluorometric methods
[25].
GR and GPx analysis were measured in the following samples:
erythrocytes (8–48 mL ), liver (40–240 mg), abdominal fat (2–
12 mg), kidney (80–480 mg), heart (80–480 mg) and brain (500–
3000 mg). GSH and GSSG were measured in erythrocytes
(149 mL), liver (75 mg), abdominal fat (372 mg), kidney (298 mg),
heart (149 mg) and brain (372 mg). The standard curves used for
the quantification of GSH and GSSG are provided as Figures S1
and S2.
In both cases, the activities of the enzymes were normalized to
the amount of protein by the Bradford method [26] and to the
amount of Hb in erythrocytes by the Drabkin method [27].
Oxidative stress
Determination of oxygen radical absorbance
capacity. Total plasma antioxidant capacity was measured as
the oxygen radical absorbance capacity (ORAC) [28], which
measures the level of protection from the loss of intensity of the
fluorescent molecules fluorescein, due to the action of peroxyl
radicals generated from an azo-initiator. A standard curve for
Trolox (reference compound for antioxidant capacity determina-
tion) was prepared in the range 12.5–100 mM.
Protein carbonylation. Protein concentrations in the ho-
mogenates were determined according to the method of Bradford
[26], using a standard curve between 0.125 and 0.975 mg
protein/mL standard. Preparation of homogenates from liver
aliquots, determination of the protein concentration in the
homogenates and protein separation by 10% SDS-PAGE proteins
from 250 mg liver were fractionated according to hydrophobicity,
into proteins soluble at low ionic strength, mostly water-soluble
proteins, and proteins soluble at high ionic strength, mostly
hydrophobic proteins. After homogenization, each liver fraction
(300 mL) and plasma (25 mL) were independently incubated with
1 mM fluorescein-5-thiosemicarbazide (FTSC) in the dark as
previously described [29,30]. After incubation, the proteins were
precipitated with an equal volume of 20% TCA (v/v), centrifuged
and finally, re-dissolved in urea buffer (7 M urea, 2 M thiourea,
2% CHAPS, 0.5% Pharmalyte 3–10, 0.5% IPG 3–10 buffer and
0.4% DTT). To evaluate the protein carbonyl levels, 30 mg of each
sample were subjected to one-dimensional (1-DE) 10% SDS-
PAGE [31] and run in a Mini-protean 3 cell (Bio-Rad). After
electrophoresis, FTSC-tagged proteins were visualized by exposing
the gel to a UV transilluminator Molecular Imager Gel Doc XR
System (Bio-Rad) equipped with a 520 nm band-pass filter
(520DF30 62 mm) and the scanned one-dimensional gels were
analysed with the 1-D gel analysis software LabImage 1D from
Kapelan Bio-Imaging Solutions (Halle, Germany). Finally, the
scanned analysed gels were stained overnight with the Coomassie
dye PhastGel Blue R-350 (GE Healthcare, Little Chalfont, UK) to
visualize the total amount of protein in each sample. The global
protein carbonylation level for each sample was quantified based
on the overall optical volume of each lane in the FTSC-stained 1-
D electrophoresis gel, whereas the oxidation level of a specific
protein band was estimated by its optical intensity (peak height).
Oxidized albumin (1 to 14 mg) was used as a positive control.
Oxidized LDL. Plasma oxidized LDL (LDL-ox) was deter-
mined with an ELISA kit from Cusabio Biotech, by measuring the
absorbance at 450 nm on a PowerWave XS2 spectrophotometer
from BioTec Instruments, Inc., (Winooski, VT, USA).
Malondialdehyde (MDA). MDA concentrations were mea-
sured in homogenized liver (80 mg of sample), kidney (80 mg),
abdominal fat (80 mg), heart (10 mg) and brain (400 mg) with
fluorescence detection [32]. The fluorescence at 515 nm excitation
wavelength and 548 nm emission wavelength was determined on
an LS50B spectrofluorimeter (Perkin Elmer, Alabama, USA).
Determination of isoprostane 15-F2t-IsoP. Urine 15-F2t-
IsoP was determined by GC/negative ion chemical ionization/MS
(GC-NICI-MS) following the method of Milne et al. [33]. Briefly,
after addition of the deuterated internal standard [2H4]-15-F2t-
IsoP to 250 mL of urine, the samples were subjected to solid phase
extraction (SPE) purification, with a C18 Sep-Pak column and a
silica Sep-Pak column (both from Waters Associates, Milford, MA,
USA). The F2-Isoprostanes were derivatized to pentafluorobenzyl
(PFB) esters and further purified by thin layer chromatography
(TLC) using 15-F2t-IsoP methyl ester as the reference compound
with an RF value identical to the analyte. Finally, the pure
derivatized analytes were converted to trimethylsilyl ether
Cardiovascular Disease Parameters and Oxidative Stress in SHROB Rats
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derivatives and analysed by GC-NICI-MS using a Shimadzu
QP201 instrument (Tokyo, Japan), fitted with a DB1701 fused
silica capillary column (15 m60.25 mm i.d., 0.25 mM film
thickness) from Agilent (J & W Scientific, Folsom, CA, USA).
The 15-F2t-IsoP ion monitored was the carboxylate anion at m/z
569. Representative chromatograms used for the determination of
15-F2t-IsoP are provided as Figure S3. The final results are
expressed in ng/mg creatinine. Creatinine levels from the urine
samples were determined by a colorimetric method using a
commercial kit from C-cromatest Linear Chemicals (Barcelona,
Spain) by measuring absorbance at 510 nm on a SpectraMax M5
spectrophotometer (Molecular Devices, Sunnyvale, CA, USA).
Statistical analysis
The different analytical determinations in the biological samples
were carried out in duplicate or triplicate, depending on the
method. Results are expressed as the mean + SEM. The non-
parametric Mann-Whitney U’s test was applied to analyse the
significant differences (P,0.05) between groups. The SPSS
IBM19 package for Windows was used throughout.
The weight distribution between the groups of rats at each of
the 15 time points was compared using the Wilcoxon Rank Sum
test. Due to the large number of comparisons, a multi-test
procedure that applies multiple comparisons as is known as the
false discovery rate (FDR) [34] correction, with Simes’ method
[35] was used. With this procedure a comparison was considered
statistically significant if the corresponding p-value was lower than
or equal to the specific a-corrected value for the comparison. This
analysis was performed using the statistical software STATA 12.0.
Results
Cardiovascular disease risk factors
The SHROB rats were already obese at week 16, with a body
weight twice that of the WKY rats (48369 g versus 22164 g).
Moreover, while the WKY rats maintained a constant body weight
up to week 27, the SHROB rats showed an increase from
476.8615.9 g at week 16 to 605.6619.5 g at week 27. Figure S4
shows the evolution of body weight of the SHROB and WKY rats
during the study.
Abdominal fat at the end of the study, expressed as percentage
of body weight was 50% higher in the SHROB than in the WKY
rats (Table 1).
Plasma lipid profile. The SHROB rats presented signifi-
cantly higher (P,0.01) levels of plasma total cholesterol, LDL-
cholesterol, HDL-cholesterol and triglycerides than the WKY rats
(Table 1). In particular, the SHROB rats showed a ninefold
increase in total cholesterol and more than a tenfold increase in
triglycerides, compared to the WKY rats. Plasma levels of both the
anti-atherogenic ApoA1 and the pro-atherogenic Apo B100 were
also significantly higher (P,0.01) in the SHROB rats than in the
WKY rats (+33% and +62%, respectively).
Glycaemia. No significant differences were observed in
fasting plasma glucose, OGTT or in glycated Hb between the
SHROB and WKY rats. In contrast, plasma insulin was
significantly higher (P,0.01) in the SHROB rats than in the
WKY rats (1.060.3 nM versus 0.360.1 nM, respectively), and
consequently, the HOMA index was also higher in the SHROB
rats (Table 1).
Blood pressure. Both systolic and diastolic blood pressure
were significantly higher (P,0.001) in the SHROB rats
(193612 mmHg and 13565 mmHg, respectively) than in the
WKY rats (12162 mmHg and 10662 mmHg) (Table 1).
Endothelial dysfunction. ICAM-1 and VCAM-1 were
measured as markers of endothelial dysfunction; considered the
earliest stage in the atherosclerosis process. ICAM-1 showed an
84% increase in plasma levels in the SHROB rats compared to the
WKY rats (P,0.001). No significant differences were found in
plasma VCAM-1 between the SHROB and WKY rats (Table 1).
Inflammation. Plasma C-reactive protein, determined as a
marker of inflammation, was 65% higher in the SHROB rats than
in the WKY rats (P,0.001) (Table 1).
Thrombotic activity. The SHROB rats presented signifi-
cantly higher (P,0.001) plasma levels of PAI-1 than the WKY rats
(6.460.3 mg/mL versus 11.660.5 mg/mL, respectively) (Ta-
ble 1).
Endogenous antioxidant systems
Endogenous antioxidant systems were evaluated in erythrocytes,
tissues and organs of the SHROB and WKY rats at the end of the
study (Table 2).
SOD and CAT activity. The activity of the endogenous
antioxidant enzymes was measured in erythrocytes, liver, abdom-
inal fat, kidney and heart. No significant differences in SOD
activity between SHROB and WKY rats were observed in any of
the samples analysed. As regards CAT activity, brain was the only
organ where significant differences (P,0.01) were found between
the SHROB and WKY rats.
Glutathione system. The status of the glutathione system
was evaluated by quantifying the two forms of glutathione (GSH
and GSSG) to calculate the GSH/GSSG ratio; and by measuring
the activity of the associated enzymes (GR, which regenerates
reduced glutathione; and GPx, which catalyses the oxidation of
GSH to GSSG). Higher concentrations of GSH in liver (P,0.01),
abdominal fat (P,0.05) and brain (P,0.01) were found in the
SHROB rats than the WKY rats. GSH/GSSG was significantly
(P,0.05) higher in the adipose tissue of the SHROB rats. GPx
activity was also higher in the abdominal fat tissue (P,0.001) and
brain (P,0.01) of the SHROB rats. In contrast, higher
concentration of GSSG were found in the heart of the SHROB
rats than in the WKY rats (P,0.01) and the SHROB rats showed
lower GPx activity in erythrocytes and in liver (P,0.05) and lower
GR activity in liver (P,0.05).
Oxidative stress
Several biomarkers of OS were measured in blood, urine and
different organs in the SHROB and WKY rats (Table 3). Plasma
antioxidant capacity, as determined by ORAC assay, was
significantly (P,0.05) higher in the SHROB than in the WKY
rats. Lipid oxidation was evaluated by determining oxidized LDL
in plasma, MDA in liver, kidney, abdominal fat, heart and brain,
and 15-F2t-IsoP in urine. Oxidized LDL in plasma was 50%
higher in the SHROB rats than in the WKY rats, although this
increase did not reach significance, due to the high interindividual
variability of this parameter. Similarly, isoprostane 15-F2t-IsoP in
urine was non-significantly higher in the urine of SHROB rats.
Creatinine was higher in SHROB rats than in WKY rats (68 mg/
dL SEM 9 vs 58 mg/dL SEM 7); since 15-F2t-IsoP is expressed
per mg of creatinine, the higher values of this isoprostane in the
SHROB rats is not an artefact resulting from increased creatinine
values. In contrast, MDA in abdominal fat was significantly lower
(P,0.05) in SHROB rats than in WKY rats and overall protein
oxidation-measured as total carbonyls-was lower in the SHROB
than in the WKY rats in both the low and high ionic strength
fractions of liver proteins (P,0.05) as well as in plasma
(P= 0.0571).
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Discussion
SHROB rats represent a particularly interesting animal model
for MetS, a situation prior to the onset of type-2 diabetes or CVD,
in which the different metabolic alterations may be addressed
without the use of drugs. The aim of the present study was to
contribute to the description of this animal model, by examining
parameters related to cardiovascular function, inflammation and
oxidative stress not previously reported.
Total cholesterol, triglycerides, fasting glucose, insulin, glycated
haemoglobin and blood pressure, have been examined before in
SHROB rats [15,17] and in the related SHRSP (stroke-prone
spontaneously hypertensive rat) model, after supplementation with
soybean oil [36]. Our results concord with previous reports except
for glycaemia; some authors found hyperglycaemia [15,37,38]
while others reported normoglycaemia, [17,39], as we do. Anti-
atherogenic ApoA1 and pro-atherogenic Apo B100 are now
included in the lipid profile. Certain markers of endothelial
dysfunction (ICAM-1 and VCAM-1), inflammation (C-reactive
protein) and thrombotic activity (PAI-1) are also reported here for
the first time.
The SHROB rats exhibited significant alterations in abdominal
fat, plasma lipid profile (total cholesterol, LDL-cholesterol, HDL-
cholesterol, triglycerides, apoA1, apoB100), insulin, blood pres-
sure, ICAM-1, C-reactive protein and PAI-1 (Table 1). In many
of these parameters (lipid profile, markers of endothelial dysfunc-
tion, inflammation and thrombotic activity), the values in the
SHROB rats were at least 50% higher than in the WKY rats.
Impairment of endothelial function in SHROB rats has previously
been related to alterations in the nitric oxide pathway and the
presence of visceral prostaglandins derived from perivisceral
adipose tissue [36,37] All these results are consistent with high
circulating fat, visceral fat accumulation and the state of low-level
inflammation that precedes insulin resistance [40]. Inflammation
appears to be the link between obesity and the development of
insulin resistance in MetS [41]. The mutation (fak) in the leptin
receptor of SHROB rats that impairs the ability of leptin to
regulate fat intake would explain these effects with a direct relation
to an excess of fat.
Since OS is a complex process, where there are different
interactions between endogenous antioxidants systems, progress of
oxidation in biomolecules and levels of circulating exogenous
antioxidants [42], we decided to measure markers corresponding
to each one of these components of OS. The picture that emerges
from our results is of a marked difference between systemic OS (as
measured via the endogenous antioxidant system in erythrocytes
and oxidized LDL in plasma) and OS in organs (as measured via
the endogenous antioxidant system in tissues and organs, and via
final lipid and protein oxidation products in organs and in urine).
Both SOD and GPx activities in erythrocytes were significantly
reduced in the SHROB rats, and this attenuation of the
endogenous defence system was concomitant with a 50% increase
in LDL oxidation. This is consistent with the preceding
observations related to CVD biomarkers, since OS, particularly
low SOD activity, has been shown to be present in subjects with
MetS who also show high C-reactive protein levels [4]. However,
this systemic OS was not immediately translated to the different
organs, since the levels of MDA in liver and kidney and of 15-F2t-
IsoP in urine were not significantly modified in the SHROB rats.
Indeed, compared to the WKY rats, the SHROB strain presented
a significant increase in GSH in liver, abdominal fat and brain as
well as a significant decrease in overall protein carbonylation and
lipid oxidation in abdominal fat. We found that, in SHROB rats,
OS may present later than other reported organ disturbances such
Table 1. CVD risk factors evaluated in the plasma of SHROB and WKY rats (mean value and SEM)1.
Category Parameter SHROB WKY
SEM SEM
Physical measurements Abdominal fat (% bw) 6?7** 0?4 4?3 0?2
Plasma lipid profile Total cholesterol (mM) 8?3** 1?2 3?3 0?2
LDL-cholesterol (mM) 0?4* 0?1 0?1 0?004
HDL-cholesterol (mM) 2?9* 0?2 1?9 0?1
Total triglycerides (mM) 40?0** 0?0 5?6 1?1
Apo A1 (mg/dL) 68?3* 1?9 51?4 5?0
Apo B100 (mg/dL) 205?4* 18?7 126?8 5?3
Glycaemia Glucose (mM) 3.4 0.1 3.5 0.1
Insulin (nM) 1?0** 0?2?9 0?3 0?1
HOMA index 15?6** 2?4 5?6 1?1
OGTT (AUC) 5016?3 177?4 4494?0 122?8
Glycated Hb (%) 6?8 0?4 6?4 0?4
Blood pressure Systolic blood pressure (mmHg) 193?2** 12?5 121?0 2?2
Diastolic blood pressure (mmHg) 134?8** 5?2 106?5 1?7
Endothelial dysfunction VCAM-1 (mg/mL) 2?7 0?3 3?4 0?6
ICAM-1 (ng/mL) 1?0** 0?1 0?5 0?03
Inflammation C reactive protein (pg/mL) 285?9** 22?0 172?8 14?4
Thrombotic activity PAI-1 (mg/mL) 11?6** 0?5 6?4 0?3
1SHROB, Spontaneously Hypertensive Obese; WKY, Wistar Kyoto; OGTT, oral glucose tolerance test; VCAM-1, vascular cell adhesion molecule-1; ICAM-1, intercellular
adhesion molecule-1; PAI-1, plasminogen activator inhibitor-1.
Statistically significant differences between the samples are indicated by * (P,0.05), ** (P,0.01) and *** (P,0.001).
doi:10.1371/journal.pone.0104637.t001
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as increased renal macrophage infiltration [43]. Also, it should be
noted that even if total protein carbonylation in SHROB rats is
shown to be lower than in WKY rats, we recently reported that
key proteins involved in redox homeostasis, such as aldehyde
dehydrogenase mitochondrial, protein disulphide-isomerase A3 or
protein disulphide-isomerase, suffer higher oxidation in SHROB
rats than in WKY rats [44]. Finally, the higher plasma antioxidant
capacity in the SHROB rats, concordant with the lower protein
carbonylation found in SHROB plasma may be the result of the
activation of defence mechanisms that are not observed to have
been overwhelmed in most organs. The observed differences
between the different markers of OS, corresponding to different
stages and elements of this process, emphasize the need to carry
Table 2. Endogenous antioxidant systems in SHROB and WKY rats (mean value and SEM)1.
Organ Parameter SHROB WKY
SEM SEM
Erythrocytes SOD (U/g Hb) 768?0 224?0 1444?0 161?0
CAT (mmol/min/g Hb) 51?9 4?1 41?5 13?1
GR (U/g Hb) 0?9 0?1 0?9 0?1
GPx (U/g Hb) 51?5* 10?3 101?5 14?4
Liver SOD (U/g mg prot) 8?3 0?5 8?7 0?6
CAT (mmol/min/mg prot) 70?8 9?8 81?1 10?9
GR (mU/mg prot) 66?7* 3?1 88?8 8?3
GPx (mU/mg prot) 245?4* 31?0 383?8 37?1
GSH (nmol/mg prot) 61?2** 9?6 29?9 2?6
GSSG (nmol/mg prot) 133?7 12?1 61?2 9?6
GSH/GSSG 0?5* 0?1 0?5 0?1
Abdominal fat SOD (U/g mg prot) 4?2 0?7 6?5 1?4
CAT (mmol/min/mg prot) 27?8 4?9 28?3 2?5
GR (mU/mg prot) 31?2 7?3 28?3 2?1
GPx (mU/mg prot) 38?7** 2?6 15?8 4?0
GSH (nmol/mg prot) 110?4* 24?9 41?7 6?4
GSSG (nmol/mg prot) 49?8 4?8 47?7 3?0
GSH/GSSG 2?2* 0?5 0?9 0?1
Kidney SOD (U/g mg prot) 2?2 0?3 2?8 0?4
CAT (mmol/min/mg prot) 24?1 3?1 33?5 7?6
GR (mU/mg prot) 47?1 11?72 41?64 3?93
GPx (mU/mg prot) 57?2 9?07 48?0 3?82
GSH (nmol/mg prot) 33?4 7?4 36?7 3?7
GSSG (nmol/mg prot) 0?5 0?1 0?6 0?1
GSH/GSSG 71?0 18?1 64?5 8?6
Heart SOD (U/g mg prot) 6?0 0?5 5?6 0?7
CAT (mmol/min/mg prot) 15?1 0?6 13?4 1?1
GR (mU/mg prot) 23?6 1?4 27?4 2?3
GPx (mU/mg prot) 146?6 9?9 159?6 9?0
GSH (nmol/mg prot) 21?5 2?8 18?1 2?1
GSSG (nmol/mg prot) 6?4** 0?6 4?5 0?3
GSH/GSSG 3?4 0?5 4?0 0?5
Brain SOD (U/g mg prot) 8?0 0?2 7?4 1?5
CAT (mmol/min/mg prot) 6?4** 0?9 2?2 0?7
GR (mU/mg prot) 67?4 7?3 49?8 3?7
GPx (mU/mg prot) 49?0** 5?3 30?9 1?5
GSH (nmol/mg prot) 87?2** 16?5 24?2 7?3
GSSG (nmol/mg prot) 5?2 0?4 3?0 1?0
GSH/GSSG 16?8 3?4 8?0 3?5
1SHROB, Spontaneously Hypertensive Obese; WKY, Wistar Kyoto; SOD, superoxide dismutase; CAT, catalase; GR, glutathione reductase; GPx, glutathione peroxidase;
GSH, glutathione; GSSG, glutathione disulphide; Hb, haemoglobin.
Statistically significant differences between the samples are indicated by * (P,0.05), ** (P,0.01) and *** (P,0.001).
doi:10.1371/journal.pone.0104637.t002
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out this kind of integrated evaluations of OS in in vivo studies on
metabolic syndrome.
The results presented here provide an updated picture of CVD-
related markers in SHROB rats. In blood, the animals show
elevated levels of markers related to inflammation, endothelial
dysfunction, thrombotic activity, insulin resistance and oxidative
stress (C-reactive protein, total cholesterol, LDL-cholesterol,
triglycerides, apoA1, apoB100, abdominal fat, blood pressure,
ICAM-1 and PAI-1, insulin and oxidized LDL). In other organs
(abdominal fat, liver and brain) the glutathione system is activated
and oxidative stress remains low, according to the observed
concentrations of final lipid and protein oxidation products. All
these observations are consistent with a pre-diabetic obese status of
SHROB rats with a high risk of developing CVD that may be used
to evaluate the effects of nutritional interventions on the metabolic
alterations present in MetS.
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